Gogalic Selma
Austrian Institute of Technology, Austria
Title: A multiplexed protein based urine chip to distinguish recurrent from non-recurrent BCa
Biography
Biography: Gogalic Selma
Abstract
Cancer of the bladder (BCa) is killing thousands of people a year. It is the fourth leading cause of cancer in men (US) and the costs for treatment are rising due to high relapse rate (50% within 2 years). To intervene recurrence of BCa routine cytology and cystoscopy are done, representing the gold standard. Nevertheless these diagnostic tools are expensive, time consuming, invasive and lead to urinary infections in up to 16% of patients. Therefore detection in urine to monitor recurrent BCa is in focus. Commercial urine based tests measure single markers, such asNMP-22 and BTA. However, none of them has proofed good sensitivity and specificity. To overcome the problem of low sensitivity and specificity we have developed a protein microarray based on a unique panel of 10 biomarkers. This BCa chip consists of ARChip Epoxyglass-slidesspotted with captureantibodies to bindthe respective biomarkers. The binding is then detected with a secondary biotinylated antibody and Dy647-streptavidin (simultaneouslywithin5hrs). The chip was validated using samples of 76 patients. ROC curves were generated and the optimal cut-off value determined. Expression of fourbiomarkers(DCN, VEGF, IL-8, EN-2) out of 10wassignificantlydifferentbetweenpatientsamples with recurrent and non-recurrent BCa. Those are actually subject to a multi center study with 1013 patients.